Peptide Therapy

Approved peptide medicines

Peptides have a long and separate history as mainstream medicines. A 2022 review notes that since insulin was introduced nearly a century earlier, more than 80 peptide drugs had been approved, with uses that include diabetes, cancer, HIV infection, chronic pain and osteoporosis. A 2026 sports-medicine review identifies GLP-1 receptor agonists such as semaglutide as the one peptide class in its scope with reproducible randomized evidence. These licensed medicines are prescribed for defined conditions and are not the subject of this page, and their evidence does not carry over to the products described below.

Origins of the wellness peptides

The peptides most associated with wellness use began as laboratory or drug-development compounds. BPC-157, a peptide described as derived from gastric juice, was reported by a research group in Zagreb, Croatia, in the early 1990s; one review dates its first description to 1992 and another to 1993. Ipamorelin was described in 1998 by researchers at Novo Nordisk as a pentapeptide that released growth hormone selectively in rats and swine, and was presented as a candidate for clinical development.

CJC-1295 was studied in the mid-2000s as a long-acting analog of growth hormone-releasing hormone (GHRH), with trials in healthy adults published in 2006. These compounds entered clinical research programs, but the sources reviewed here do not report any of them reaching approval for the wellness, recovery or anti-aging purposes for which they are now promoted.

Spread into wellness and sports settings

Recent reviews describe a fast-growing market outside conventional prescribing. A 2026 review reports that injectable peptides are increasingly used without prescriptions for cosmetic and athletic enhancement, driven by digital marketing and social media. A 2026 endocrinology review describes growth-hormone-axis peptides sold as research compounds and taken according to online self-administration protocols, and a sports-medicine review concludes that clinical adoption has outpaced high-quality evidence.

What the peptides are

The products grouped under peptide therapy are short chains of amino acids that differ widely in structure and proposed action. BPC-157 is a synthetic pentadecapeptide of 15 amino acids, ipamorelin is a pentapeptide, and GHK is the tripeptide glycyl-L-histidyl-L-lysine, which is usually sold as its copper complex, GHK-Cu. A 2026 review of GHK-Cu cautions that the literature often treats it as one ingredient even though its chemical form varies with formulation.

Names and product labels

BPC stands for body protection (or body protective) compound. TB-500 is not the same as thymosin beta-4: the World Anti-Doping Agency (WADA) list names it as a derivative of thymosin beta-4, while clinical trials have used the full peptide. CJC-1295 is sold with or without a drug affinity complex (DAC), and a 2026 review reports that the version without DAC is essentially uncharacterized in peer-reviewed human studies. Products are often labeled as research compounds or research peptides rather than as medicines.

Approved and unapproved peptides

Reviewers draw a firm line between approved peptide drugs used under medical supervision, such as semaglutide and tirzepatide, and unapproved experimental peptides such as BPC-157 and TB-500. Within the growth-hormone axis, tesamorelin has randomized trial data for an approved indication, HIV-associated lipodystrophy, whereas most secretagogues have only early-phase human studies. The term peptide therapy in wellness marketing usually refers to the unapproved group.

Routes and settings

Peptides in this setting are given by several routes. A systematic review reports that athletes use BPC-157 by intra-articular and intramuscular injection and in oral forms, and the small human studies of BPC-157 used knee injection, bladder instillation and intravenous infusion. CJC-1295 was given by injection under the skin in its trials. GHK-Cu appears mostly in topical cosmetic products. Sources describe supply both through clinics and through online vendors that sell without a prescription.

Combinations and cycles

A 2026 review compares online self-administration protocols with the published evidence. It reports that CJC-1295 without DAC is commonly combined with ipamorelin, a practice called stacking, and that growth hormone-releasing peptides are typically taken one to three times daily in cycles of about 8 to 16 weeks followed by 4 to 6 weeks off. The authors also describe co-use with anabolic-androgenic steroids in physique-oriented settings. These regimens come from grey literature and have not been tested in trials.

Recovery and tissue repair

The most common claims concern injury recovery. Reviews describe BPC-157 and thymosin derivatives being promoted to speed the repair of muscle, tendon, ligament and bone injuries, with BPC-157 increasingly used by clinicians and athletes despite the lack of approval. These claims rest mainly on animal studies, as the Research and Evidence section explains.

Body composition, aging and appearance

Growth-hormone secretagogues such as ipamorelin and CJC-1295 are promoted for performance and body recomposition, on the reasoning that they raise growth hormone and insulin-like growth factor 1 (IGF-1). GHK-Cu is marketed for skin aging and cosmetic uses. A 2026 review links some injectable peptide use to cosmetic enhancement trends spread through social media. Reviewers describe these benefits as putative and not established in controlled human studies.

BPC-157

A 2025 systematic review searched PubMed, Cochrane and Embase to June 2024 and included 36 studies, 35 of them preclinical. In animal models BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries. The single clinical study was a retrospective series in which 7 of 12 people given a knee injection for chronic knee pain reported relief for more than six months. The review found no clinical safety data and rated the evidence as level IV and V.

A 2025 narrative review counts three human pilot studies: knee injections in 16 patients, bladder instillation in 12 patients with interstitial cystitis, and intravenous infusion in two healthy adults. None had a control group. The two reviews describe the knee series differently, and both conclude that human data are extremely limited and that BPC-157 should be treated as investigational.

Growth-hormone secretagogues

Two randomized, placebo-controlled, ascending-dose trials of CJC-1295 in healthy adults aged 21 to 61 found that one injection raised mean growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days, with no serious adverse reactions reported. These trials measured hormone levels, not health, performance or aging outcomes.

In a phase 2 randomized, double-blind trial in 114 patients after bowel surgery, intravenous ipamorelin did not differ significantly from placebo in time to tolerating a solid meal (median 25.3 versus 32.6 hours, p = 0.15). A 2026 review reports no controlled efficacy data for performance endpoints for most secretagogues and no human studies of CJC-1295 without DAC.

Thymosin beta-4 and GHK-Cu

Human trials of thymosin beta-4 have used the full peptide in medical settings rather than TB-500. In one phase 2 trial, nine people with severe dry eye used thymosin beta-4 eye drops or a vehicle for 28 days, and the treated group showed less discomfort and corneal staining at day 56. That small ophthalmic study does not address injected TB-500. For GHK-Cu, a 2026 evidence-mapping review found consistent preclinical effects but sparse clinical data: a 13-person study after laser resurfacing was negative on objective endpoints, and an 18-person eyebrow study reported positive results without defining the product.

Overall picture

A 2026 structured review of injectable peptides in sports medicine concludes that regenerative peptides such as BPC-157 and thymosin derivatives, and secretagogues such as CJC-1295 and ipamorelin, remain investigational, with uncertain safety and product quality. Only GLP-1 receptor agonists had reproducible randomized evidence, for knee osteoarthritis symptoms largely through weight loss. No systematic review or randomized trial of peptide therapy as delivered in wellness clinics was found in the sources reviewed.

Missing human safety data

Reviewers state that most of these peptides lack established human safety profiles. The 2025 BPC-157 review found no clinical safety data and notes possible harms from unregulated manufacturing, contamination and unknown clinical effects. A 2026 review lists potential risks of unapproved injectables that include pathological blood-vessel growth, cancer promotion, cardiovascular stress and supraphysiological hormone signaling, presented as concerns rather than measured rates.

For growth-hormone-axis peptides, a 2026 endocrinology review reports adverse effects that include raised prolactin and cortisol, appetite changes, disturbed blood glucose, fluid retention, muscle and joint pain and injection-site reactions. It describes sustained IGF-1 elevation as a biologically plausible cancer concern while stating that this does not establish that any specific peptide causes cancer in humans.

Product quality and purity

Products sold outside regulated supply chains may not contain what the label states. A 2018 Belgian laboratory study of the ten most frequently encountered falsified peptide drugs, bought from three suspected illegal online pharmacies, found wide variation in amount per unit, purity of 5 to 75 percent for cysteine-containing peptides, and arsenic and lead, with some samples up to ten times the toxicity limit for injected drugs. Reviews also cite uncertain sterility, dosing accuracy and composition as concerns for injected peptides.

Anti-doping status

The WADA Prohibited List for 2026 names BPC-157 under S0, non-approved substances. Under S2 it lists GHRH analogues including CJC-1295, growth hormone secretagogues including ipamorelin, and growth hormone-releasing peptides, and it lists thymosin beta-4 and its derivatives such as TB-500 among prohibited growth factors. These are prohibited at all times, in and out of competition. A 2025 review reports that BPC-157 was specifically named in 2022. Athletes subject to anti-doping rules face sanctions under those sports rules if these substances are detected.

Care boundaries

Reviewers advise clinicians to ask about non-prescribed peptides when assessing unexplained symptoms or laboratory results, and to discuss uncertain efficacy, product quality and anti-doping implications. Peptide products should not delay or replace assessment and care for injuries, hormonal symptoms or other health concerns, and approved peptide medicines such as insulin are distinct products with their own prescribing information.